Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors
- PMID: 37139724
- DOI: 10.1158/2159-8290.CD-23-0199
Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors
Abstract
In this issue of Cancer Discovery, Salem and colleagues report a combination therapy for immune-checkpoint inhibitor (ICI) myocarditis using high-dose glucocorticoids, abatacept, and the JAK inhibitor ruxolitinib. The apparent efficacy of their strategy and an accompanying animal model provide further evidence for common immune mechanisms underlying ICI toxicities. See related article by Salem et al., p. 1100 (2).
©2023 American Association for Cancer Research.
Comment on
-
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.Cancer Discov. 2023 May 4;13(5):1100-1115. doi: 10.1158/2159-8290.CD-22-1180. Cancer Discov. 2023. PMID: 36815259
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources